Tecartus First CAR T-Cell Therapy FDA Approved for Patients with Mantle-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 46
- Publication type:
- Article
Works matching IS 21534888 AND DT 2020 AND VI 11 AND IP 5
Results: 35
1
2
FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 46
- Publication type:
- Article
3
Opportunities for Innovation in Value-Based Payments in Oncology.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 45
- By:
- Publication type:
- Article
4
Can We Lower the Cost of Cancer Care?
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 44
- By:
- Publication type:
- Article
5
Patient Engagement in the Digital Age: The Impact of Digital Therapeutics in Oncology Care.
- Published in:
- 2020
- By:
- Publication type:
- Interview
6
Personalized Vaccine plus Immune Checkpoint Inhibitor a Promising Approach to Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 40
- By:
- Publication type:
- Article
7
Venetoclax plus Azacitidine Combination Improves Overall Survival in Patients with AML.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 39
- Publication type:
- Article
8
Pembrolizumab New Standard of Care for Relapsed or Refractory Classical Hodgkin Lymphoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 39
- By:
- Publication type:
- Article
9
Prevalence of Germline Mutations Surprisingly High in Young Adults with Early-Onset Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 38
- By:
- Publication type:
- Article
10
Effective Targeted Therapies in CCA: IDH1 and FGFR.
- Published in:
- 2020
- Publication type:
- Interview
11
Exploring Gender-Based Differences in the Incidence, Diagnosis, and Treatment of Cholangiocarcinoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 34
- Publication type:
- Article
12
Adjuvant Immunotherapy with Ipilimumab Improves Survival in Patients with Stage III Melanoma in the Real-World Setting.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 32
- By:
- Publication type:
- Article
13
Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 31
- By:
- Publication type:
- Article
14
Cabozantinib plus Nivolumab Combination Potential New First-Line Option for Patients with Advanced Renal-Cell Carcinoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 30
- By:
- Publication type:
- Article
15
Olaparib a New Option for Men with Metastatic Prostate Cancer and BRCA Mutation.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 29
- By:
- Publication type:
- Article
16
LIBTAYO<sup>®</sup> (cemiplimab-rwlc) injection 350mg.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 24
- Publication type:
- Article
17
Washington and Public Policy Update During COVID-19.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 23
- Publication type:
- Article
18
Impact of COVID-19 on Economic Trends in Oncology.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 22
- Publication type:
- Article
19
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 22
- Publication type:
- Article
20
Drug Manufacturers' Response to the Pandemic.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 21
- Publication type:
- Article
21
INJECTION RUXIENCE™ (rituximab-pvvr).
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 16
- Publication type:
- Article
22
RUXIENCE™ (rituximab-pvvr): A BIOSIMILAR* IN THE HEMATOLOGY SETTING—BUILT BY PFIZER.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 13
- Publication type:
- Article
23
Bortezomib, Lenalidomide, and Dexamethasone Remains Standard of Care for Treatment of Patients with Newly Diagnosed Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 12
- By:
- Publication type:
- Article
24
Selpercatinib, First Treatment for Patients with Thyroid Cancer and RET Mutation, Shows Durable Responses.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 11
- Publication type:
- Article
25
Advances in New Therapies Attributed to Reduction in Lung Cancer Mortality.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 11
- Publication type:
- Article
26
Capmatinib Shows Substantial Antitumor Activity in Treatment-Naïve Patients with Metastatic NSCLC and MET Exon 14 Mutations.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 11
- By:
- Publication type:
- Article
27
Maximize OCM & Telehealth Payments: A Personalized Digital Therapeutic for Remote Care Management.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 9
- Publication type:
- Article
28
Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 8
- Publication type:
- Article
29
Immune Checkpoint Inhibitors Have No Harmful Effect on Patients with Cancer and COVID-19.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 8
- By:
- Publication type:
- Article
30
COVID-19 a Perpetual Challenge, Requiring Ongoing Vigilance.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 7
- By:
- Publication type:
- Article
31
Biosimilars May Help Bridge the Transition From Fee-for-Service to Value-Based Care.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 2
- Publication type:
- Article
32
AACR's Cancer Disparities Inaugural Report Addresses Care Inequities.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 1
- By:
- Publication type:
- Article
33
Challenges for the Multiple Vaccine Candidates Targeting COVID-19.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 1
- Publication type:
- Article
34
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 1
- By:
- Publication type:
- Article
35
COVID-Related Death Rate Tripled in Patients with Cancer versus the General Population.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 5, p. 1
- By:
- Publication type:
- Article